Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
ACUTE MYELOID LEUKEMIA TARGETED THERAPEUTIC AGENT WITH REDUCED DRUG SIDE EFFECTS
Document Type and Number:
WIPO Patent Application WO/2016/006921
Kind Code:
A1
Abstract:
The present invention relates to an acute myeloid leukemia targeted therapeutic agent with reduced drug side effects, and is useful in treatment, prevention and alleviation of acute myeloid leukemia due to having an inhibitory activity against acute myeloid leukemia and an inhibitory activity against FLT3 point mutation species.

Inventors:
SIM TAE BO (KR)
YOON HO JONG (KR)
HUR WOO YOUNG (KR)
Application Number:
PCT/KR2015/007030
Publication Date:
January 14, 2016
Filing Date:
July 07, 2015
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
KOREA INST SCI & TECH (KR)
International Classes:
A61K31/519; A61K31/506; A61P35/02
Domestic Patent References:
WO2007115822A12007-10-18
Foreign References:
KR20110044053A2011-04-28
KR20150001967A2015-01-07
Other References:
SNEGAROFF, KATIA ET AL.: "Direct metallation of thienopyrimidines using a mixed lithium-cadmium base and antitumor activity of functionalized derivatives.", ORG. BIOMOL. CHEM., vol. 7, 2009, pages 4782 - 4788
TEMBURNIKAR. KARTIK W. ET AL.: "Antiproliferative activities of halogenated thieno[3,2-d]pyrimidines.", BIOORGANIC & MEDICINAL CHEMISTRY., vol. 22, 3 March 2014 (2014-03-03), pages 2113 - 2122, XP028835553, DOI: doi:10.1016/j.bmc.2014.02.033
DISCH. JEREMY S. ET AL.: "Discovery of Thieno[3,2-d]pyrimidine-6-carboxamides as Potent Inhibitors of SIRT1, SIRT2, and SIRT3.", J. MED. CHEM., vol. 56, 2013, pages 3666 - 3679
PARK. CHUN-HO ET AL.: "Discovery of thienopyrimidine-based FLT3 inhibitors from the structural modification of known IKKb inhibitors.", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS., vol. 24, 24 April 2014 (2014-04-24), pages 2655 - 2660, XP028665097, DOI: doi:10.1016/j.bmcl.2014.04.058
Attorney, Agent or Firm:
HALLA Patent & Law Firm (KR)
한라특허법인 (KR)
Download PDF: